Online inquiry

IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15097MR)

This product GTTS-WQ15097MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TNC gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Mus musculus
RefSeq NM_002160.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3371
UniProt ID P24821
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ15097MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1296MR IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABT-555
GTTS-WQ12466MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA NKTR-214
GTTS-WQ13898MR IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-2176
GTTS-WQ5334MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CD20-TCB (2:1)
GTTS-WQ1070MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-838
GTTS-WQ11747MR IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MK-1308
GTTS-WQ12676MR IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA OMP-18R5
GTTS-WQ3418MR IVTScrip™ mRNA-Anti-ALB, aALB03(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA aALB03
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW